desvenlafaxine SR

ApprovedSmall molecule

Pfizer

desvenlafaxine SR is one of 103 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Breast CancerActive, not recruiting

Major Depressive DisorderActive, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

desvenlafaxine SR

Pfizer

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Prolia

Amgen

Preclinical

14 7

Voltaren

Novartis

Preclinical

1 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder13 trials

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Completed· Pfizer logo

Pfizer·Phase 4·NCT01121484·439 enrolled

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Completed· Pfizer logo

Pfizer·Phase 4·NCT01056289·480 enrolled

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT01309542·1,403 enrolled

Show 10 more trials

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00863798·682 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Completed· Pfizer logo

Pfizer·Phase 4·NCT01432457·924 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00384033·638 enrolled

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Completed· Pfizer logo

Pfizer·Phase 3·NCT00831415·304 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00824291·437 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00798707·709 enrolled

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women

Unknown status·HHamilton Health Sciences Corporation·Phase 3·NCT00888862·90 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 2·NCT00619619·59 enrolled

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 2·NCT00669110·40 enrolled

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00887224·874 enrolled

Tics4 trials

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00727064·14 enrolled

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 3·NCT00329147·20 enrolled

Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 3·NCT00366652·20 enrolled

Show 1 more trial

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 3·NCT00329186·14 enrolled

Postmenopausal Women2 trials

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00406640·595 enrolled

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00369434·450 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Recruiting·JJiangsu Province Nanjing Brain Hospital·N/A·NCT06270433·80 enrolled

Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression

Unknown status·HHotel-Dieu Grace Healthcare·Phase 4·NCT01974934·30 enrolled

Adolescent2 trials

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Completed· Pfizer logo

Pfizer·Phase 3·NCT01371734·363 enrolled

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Completed· Pfizer logo

Pfizer·Phase 3·NCT01372150·340 enrolled

10 more indications

Safety and Efficacy1 trial

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00683800·2,186 enrolled

Midazolam1 trial

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

Completed· Pfizer logo

Pfizer·Phase 4·NCT00952653·28 enrolled

Female1 trial

Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females

Completed· Pfizer logo

Pfizer·Phase 1·NCT00818155·36 enrolled

Phase 11 trial

Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01190514·41 enrolled

Peripheral Neuropathy1 trial

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01050218·237 enrolled

Breast Cancer1 trial

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

Terminated·SSeoul National University Hospital·Phase 4·NCT02819921·59 enrolled

Effectiveness1 trial

Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers

Unknown status·UUniversity of Ottawa·Phase 1·NCT01101152·20 enrolled

Women1 trial

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Completed· Pfizer logo

Pfizer·Phase 1·NCT00397176·32 enrolled

Lip1 trial

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Terminated· Pfizer logo

Pfizer··NCT01353963·13 enrolled

Vasomotor Symptoms1 trial

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Completed· Pfizer logo

Pfizer·Phase 3·NCT00401245·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for desvenlafaxine SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — desvenlafaxine SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for desvenlafaxine SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

desvenlafaxine SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder13 trials

Tics4 trials

Postmenopausal Women2 trials

Efficacy and Safety2 trials

Adolescent2 trials

Safety and Efficacy1 trial

Midazolam1 trial

Female1 trial

Phase 11 trial

Peripheral Neuropathy1 trial

Breast Cancer1 trial

Effectiveness1 trial

Women1 trial

Lip1 trial

Vasomotor Symptoms1 trial

References

Drug Info

Quick Facts

Related News